Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
Ir Med J · 2026
Last updated 2026-07-22| Journal | Ir Med J, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
PRESENTATION: A 50-year-old obese male with non-insulin dependent diabetes mellitus (NIDDM) taking Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) presented with sudden, painless vision-loss from his right eye.
DIAGNOSIS: Right eye visual acuity was 6/24. There was Frisen grade IV optic nerve head (ONH) oedema. This was confirmed at imaging with ocular coherence tomography (OCT). The patient was diagnosed with non-arteritic anterior ischaemic optic neuropathy.
TREATMENT: Semaglutide was ceased.
DISCUSSION: GLP-1RAs such as Semaglutide are being increasingly recognised as a potential risk factor for NAION. A case such as this has not yet been reported in Ireland.
Verbatim abstract via PubMed 41589628 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.